• Japanese
  • Korean
  • Chinese
Cover Image

Kombiglyze XR (Type 2 Diabetes) - Analysis and Forecasts to 2020

Abstract

Kombiglyze XR (Type 2 Diabetes) - Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Kombiglyze XR (Type 2 Diabetes) - Analysis and Forecasts to 2020" provides Kombilgyze XR sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Kombiglyze XR including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Kombiglyze XR including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2010-2020 for Kombiglyze XR in each of the US and EU5 markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

TOC

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Introduction 5

  • 2.1 Diabetes 5
  • 2.2 Epidemiology 5
    • 2.2.1 Prevalence 5
    • 2.2.2 Mortality 7
  • 2.3 Etiology and Risk Factors 9
    • 2.3.1 Obesity 9
    • 2.3.2 Sedentary Lifestyle 9
    • 2.3.3 Family History and Genetics 9
    • 2.3.4 Ethnicity 9
    • 2.3.5 Old Age 9
  • 2.4 Economic Impact of Diabetes 9
  • 2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12

  • 3.1 Type 2 Diabetes Market 12
  • 3.2 Type 2 Diabetes Market Forecasts 13
  • 3.3 Type 2 Diabetes Market: Drivers and Restraints 14
    • 3.3.1 Drivers 14
    • 3.3.2 Restraints 15

4 Classification of Diabetes 16

  • 4.1 Types of Diabetes 16
    • 4.1.1 Type 1 Diabetes 16
    • 4.1.2 Type 2 Diabetes 16
    • 4.1.3 Gestational Diabetes 16
  • 4.2 Diabetes Complications 16
    • 4.2.1 Cardiovascular Disease 16
    • 4.2.2 Nephropathy 17
    • 4.2.3 Neuropathy 17
    • 4.2.4 Amputation 17
    • 4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

  • 6.1 Insulin 19
  • 6.2 Oral Medications 19
    • 6.2.1 Sulfonylureas (SUR) 19
    • 6.2.2 Biguanides (BGDs) 20
    • 6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
    • 6.2.4 Meglitinides 21
    • 6.2.5 Thiazolidinediones (TZDs) 22
    • 6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
    • 6.2.7 Oral Combination Therapy 23
  • 6.3 Other Injectionable Medications 24
    • 6.3.1 Pramlintide 24
    • 6.3.2 Exenatide 24
  • 6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Kombiglyze XR 25

  • 7.1 Introduction 25
  • 7.2 Mechanism of Action 25
  • 7.3 Clinical Studies 25
    • 7.3.1 Study of Kombiglyze XR in Patients with Inadequate Control on Diet and Exercise Alone 25
    • 7.3.2 Study of Kombiglyze XR in Patients with Inadequate Control on Prior Metformin Monotherapy 26
  • 7.4 Approval Of Kombiglyze XR 27
  • 7.5 Factors Affecting Sales of Kombiglyze XR 27
    • 7.5.1 Improved Glycemic Control 27
    • 7.5.2 Adverse Events 27
    • 7.5.3 Increased Risk of Lactic Acidosis 28
    • 7.5.4 Efficacy profile 28
    • 7.5.5 Competition 29
  • 7.6 Drug Evaluation 29
    • 7.6.1 Drug Risk Benefit Score 29
    • 7.6.2 Intensity of Competition 30
  • 7.7 Sales Forecasts 31
    • 7.7.1 Target Patient Pool for kombiglyze XR 31
    • 7.7.2 Dosing 31
    • 7.7.3 Annual Cost of Therapy 31
    • 7.7.4 Market Penetration 31
    • 7.7.5 Sales Forecasts of Kombiglyze XR 32

8 Diabetes Market: Appendix 40

  • 8.1 Market Definitions 40
  • 8.2 List of Abberiviations 40
  • 8.3 Research Methodology 40
    • 8.3.1 Coverage 41
    • 8.3.2 Secondary Research 41
    • 8.3.3 Forecasting 41
    • 8.3.4 Number of patients approved to take the drug 41
    • 8.3.5 Net Penetration of Drug 42
    • 8.3.6 Net Annual Dosing 42
    • 8.3.7 Annual Cost of Therapy 42
  • 8.4 Drug Sales Estimates Model 42
  • 8.5 Contact Us 42
  • 8.6 Disclaimer 43
  • 8.7 Sources 43

List of Tables

1.1 List of Tables

  • Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
  • Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 6
  • Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
  • Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales ($m), 2010 12
  • Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trails 13
  • Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
  • Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
  • Table 8: Diabetes Drugs Evolution 18
  • Table 9: Results of 24-Week Placebo Controlled Trial of Kombiglyze XR in Treatment Naive Patients 26
  • Table 10: Results of 24-Week Placebo Controlled Trial of Kombiglyze XR in Patients with Inadequate Control on Prior metformin Monotherapy 27
  • Table 11: Safety Comparison of Kombiglyze XR with Janumet 28
  • Table 12: Efficacy Values of Kombiglyze XR 28
  • Table 13: Efficacy Comparison of Kombiglyze XR with its Competitors 28
  • Table 14: Drug Risk Benefit Score, Kombiglyze XR 29
  • Table 15: Efficacy Comparison of Kombiglyze XR with its Competitors 30
  • Table 16: Kombiglyze XR, Type 2 Diabetes, Global, Sales Estimates ($m), 2010-2020 32
  • Table 17: Kombiglyze XR, Type 2 Diabetes, The US, Sales Estimates ($m), 2010-2020 33
  • Table 18: Kombiglyze XR, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2012-2020 34
  • Table 19: Kombiglyze XR, Type 2 Diabetes, France, Sales Forecasts ($m), 2012-2020 35
  • Table 20: Kombiglyze XR, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2012-2020 36
  • Table 21: Kombiglyze XR, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2012-2020 37
  • Table 22: Kombiglyze XR, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2012-2020 38

List of Figures

1.2 List of Figures

  • Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
  • Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 7
  • Figure 3: Diabetes, World, Mortality, 2010 7
  • Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
  • Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010-2020 13
  • Figure 6: Mechanism of Action of Sulfonylureas 19
  • Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
  • Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
  • Figure 9: Mechanism of Action of Thiazolidinediones 22
  • Figure 10: Mechanism of Action of DPP IV Inhibitors 23
  • Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 24
  • Figure 12: Kombiglyze XR, Type 2 Diabetes, Global, Sales Estimates ($m), 2010-2020 32
  • Figure 13: Kombiglyze XR, Type 2 Diabetes, The US, Sales Estimates ($m), 2010-2020 33
  • Figure 14: Kombiglyze XR, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2012-2020 34
  • Figure 15: Kombiglyze XR, Type 2 Diabetes, France, Sales Forecasts ($m), 2012-2020 35
  • Figure 16: Kombiglyze XR, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2012-2010 36
  • Figure 17: Kombiglyze XR, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2012-2010 37
  • Figure 18: Kombiglyze XR, Diabetes, Spain, Sales Forecasts ($m), 2012-2020 38
  • Figure 19: Kombiglyze XR, Type 2 Diabetes, Global, Sales Distribution (%), 2020 39
  • Figure 20: Patients Approved for the Drug 42
Show More
Pricing
Get Notified
Email me when related reports are published